Related Experiment Video

Updated: Jun 6, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

81

The Uncoupling of Disease Activity from Joint Structural Progression in Patients with Rheumatoid Arthritis Treated

Yoshiya Tanaka1, Tatsuya Atsumi2, Daniel Aletaha3

  • 1First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan. tanaka@med.uoeh-u.ac.jp.

Rheumatology and Therapy
|November 26, 2024
PubMed
Abstract

Insights

Achieving clinical remission or low disease activity in rheumatoid arthritis (RA) suppressed joint damage over 24 weeks. Filgotinib 200 mg (FIL200) also inhibited joint damage in patients with moderate or high RA disease activity compared to placebo.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Modern rheumatoid arthritis (RA) treatments aim for remission but residual disease activity's impact on joint damage is unclear.
  • This study investigates the link between clinical disease activity and structural joint progression in RA patients treated with filgotinib (FIL).

Purpose of the Study:

  • To evaluate the association between clinical disease activity levels and structural joint progression in RA patients treated with filgotinib (FIL) or adalimumab versus placebo.
  • To determine if filgotinib (FIL) demonstrates superior inhibition of structural joint damage in patients with moderate to high disease activity.

Main Methods:

  • A post hoc analysis of the FINCH 1 trial (NCT02889796) involving RA patients with inadequate response to methotrexate (MTX).
  • Patients were randomized to FIL 200 mg (FIL200), FIL 100 mg (FIL100), adalimumab, or placebo, all with background MTX.
  • Change from baseline in modified total Sharp score (mTSS), erosion score, and joint space narrowing score was assessed at 24 weeks based on CDAI disease activity categories.

Main Results:

  • At 24 weeks, minimal change in mTSS was observed across all treatment groups for patients achieving CDAI remission or low disease activity (LDA).
  • In patients with moderate disease activity (MDA) or high disease activity (HDA), FIL200 showed significantly lower mTSS change compared to placebo.
  • This suggests a potential uncoupling of clinical disease activity and structural progression with FIL200 in patients with higher disease activity.

Conclusions:

  • Achieving RA clinical remission or LDA is associated with suppressed progression of joint destruction across all evaluated treatments.
  • Filgotinib 200 mg (FIL200) uniquely inhibited joint damage compared to placebo in patients with MDA or HDA.
  • These findings indicate that FIL200 may decouple clinical disease activity from structural progression in certain RA patient subgroups.
Keywords:
Clinical remissionDisease activityFilgotinibMethotrexateRheumatoid arthritisStructural progression

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

995
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

3.7K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
142
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
113
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
96
Actin Filament Depolymerization01:19

Actin Filament Depolymerization

Actin filaments (F-actin) are composed of actin subunits. The dissociation of actin monomers can occur from either end of F-actin. The rate of dissociation is faster from the minus-end or the pointed end, where the actin subunits exist with a bound ADP, together known as ADP-actin. The depolymerization of F-actin is aided by proteins, including the actin-depolymerizing factor (ADF) and cofilin family of proteins, gelsolin, and glia maturation factor (GMF).
In F-actin, the ADF/cofilin proteins...
3.0K